USPTO Examiner ZEMAN ROBERT A - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18738385STRAIN OF SELENIUM-ENRICHED LACTIPLANTIBACILLUS PLANTARUM KD-2 AND APPLICATIONS IN PREPARING FERMENTED GOAT MILK AND GOAT MILK POWDERJune 2024April 2025Allow1011NoNo
18663247CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEMay 2024May 2025Allow1211NoNo
18609152METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSMarch 2024May 2025Allow1410NoNo
18591306Prevotella Copri CompositionsFebruary 2024April 2025Allow1310NoNo
18584070METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASESFebruary 2024May 2025Allow1520NoNo
18407367IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOFJanuary 2024February 2025Allow1411NoNo
18392708COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUEDecember 2023June 2025Allow1821NoNo
18470301SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOFSeptember 2023March 2025Allow1821NoNo
18364104NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USEAugust 2023September 2024Abandon1310NoNo
18361084METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSJuly 2023August 2024Abandon1220NoNo
18361724CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGOJuly 2023November 2024Abandon1610NoNo
18328162MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESJune 2023January 2025Allow2011NoNo
18300049MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO ANTI-PD1/PD-L1/PD-L2 ANTIBODIES AND USE OF MICROBIAL MODULATORS FOR IMPROVING THE EFFICACY OF AN ANTI-PD1/PD-L1/PD-L2 AB-BASED TREATMENTApril 2023July 2024Allow1511NoNo
18131560CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGOApril 2023September 2024Abandon1710NoNo
18193151INSECTICIDAL POLYPEPTIDES HAVING IMPROVED ACTIVITY SPECTRUM AND USES THEREOFMarch 2023April 2025Allow2421NoNo
18173288BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITESFebruary 2023January 2025Allow2311YesNo
18090413FECAL FUNGOME AND THERAPEUTIC EFFICACY OF FECAL MICROBIOTA TRANSPLANTATIONDecember 2022June 2025Allow2920NoNo
17993329COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASESNovember 2022May 2025Abandon3021NoNo
17993310Pet Food Compositions Including Probiotics and Methods of Manufacture and Use ThereofNovember 2022June 2025Allow3020NoNo
17986424METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSNovember 2022June 2023Allow710NoNo
18047477Novel Bifidobacterium Genus BacteriumOctober 2022June 2024Allow2011YesNo
17995004NOVEL USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A HUMAN RESPIRATORY SYNCYTIAL VIRUS PROTEIN AGAINST bRSV IN CATTLESeptember 2022November 2023Abandon1410NoNo
17881131METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSAugust 2022October 2022Allow200NoNo
17861587DERMAL FILLERJuly 2022December 2024Abandon2910NoNo
17862269TREATMENTS OF CANCER USING NITROUS OXIDE AND BOTULINIUM TOXINJuly 2022January 2025Allow3021YesNo
17838698COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUEJune 2022September 2023Allow1520YesNo
17834865PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASEJune 2022May 2024Allow2311YesNo
17833962COMPOSITIONS COMPRISING BACTERIAL STRAINSJune 2022November 2023Abandon1710NoNo
17731106METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSApril 2022July 2022Allow300NoNo
17711257Strain of Lactobacillus rhamnosus and Application thereof in Inhibiting Helicobacter pyloriApril 2022January 2025Allow3411NoNo
17764498PSEUDOMONAS ISOLATES AND USES THEREOFMarch 2022March 2025Allow3610NoNo
17703790IMMUNOGENIC FUSION PROTEINMarch 2022August 2024Allow2921NoNo
17692333TOXOPLASMA GONDII VACCINES AND THEIR USEMarch 2022January 2024Allow2211NoNo
17641315ANTIGEN BINDING PROTEIN AND ASSAYSMarch 2022March 2025Abandon3601NoNo
17638321METHODS OF INCREASING VACCINE EFFICACYFebruary 2022March 2025Abandon3601NoNo
17638190FISH SKIN MICROBIOMEFebruary 2022January 2025Abandon3501NoNo
17636743IMMUNOLOGICALLY ACTIVE FRAGMENTS OF TOXOPLASMA GONDIIFebruary 2022August 2024Allow3031NoNo
17651033COMPOSITIONS AND METHODS FOR PROMOTING NITRIC OXIDE PRODUCTION THROUGH AN ORAL DELIVERY SYSTEMFebruary 2022January 2025Abandon3501NoNo
17633791TEST SYSTEM FOR RECOGNIZING LEGIONELLAEFebruary 2022January 2025Abandon3501NoNo
17629269IN VITRO METHOD FOR DISCRIMINATING LATENT FROM ACTIVE TUBERCULOSISJanuary 2022January 2025Abandon3601NoNo
17571079NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOFJanuary 2022March 2025Allow3821NoNo
17597051COMPOSITIONS COMPRISING SECRETORY IgA AND PROBIOTICSDecember 2021April 2025Allow4021NoNo
17558418CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGODecember 2021August 2023Abandon2020NoNo
17554354PNEUMOCOCCAL CONJUGATE VACCINE FORMULATIONSDecember 2021May 2025Abandon4110NoNo
17548904AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIADecember 2021December 2023Allow2411NoNo
17545148PROBIOTIC BIFIDOBACTERIUM STRAINDecember 2021September 2023Abandon2110NoNo
17541546DERMAL FILLERDecember 2021December 2024Abandon3610NoNo
17533320ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USENovember 2021August 2024Allow3321YesNo
17532034Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosaNovember 2021November 2023Allow2410NoNo
17515985METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASESNovember 2021June 2024Abandon3221NoNo
17502259Penicillium oxalicum SDF-25 strain and application thereofOctober 2021March 2025Allow4111NoNo
17497157ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOFOctober 2021April 2025Abandon4231NoNo
17491889COMBINATIONS OF ANTI-STAPHYLOCOCCUS AUREUS ANTIBODIESOctober 2021January 2024Abandon2811NoNo
17483162ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA)September 2021December 2023Allow2711NoNo
17459715HELICOBACTER THERAPEUTICAugust 2021July 2023Allow2210NoNo
17430117COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGENAugust 2021June 2025Allow4721NoNo
17377475ROS KINASE IN LUNG CANCERJuly 2021February 2024Abandon3111NoNo
17253798Vaccine Used For Preventing Toxoplasma Gondii Infection And Preparation Method ThereforJuly 2021September 2022Allow2121NoNo
17309996NANOVESICLES DERIVED FROM BACTERIA OF GENUS DEINOCOCCUS, AND USE THEREOFJuly 2021January 2025Abandon4211NoNo
17368396COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIAJuly 2021December 2023Allow2911NoNo
17367812IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOFJuly 2021September 2023Allow2711YesNo
17346362MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESJune 2021July 2023Allow2511NoNo
17331536VACCINE FOR IMMUNOCOMPROMISED HOSTSMay 2021July 2023Allow2511YesNo
17324606Rapid Analysis of Cyanobacterial ToxinsMay 2021November 2022Allow1700NoNo
17243455NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USEApril 2021May 2023Allow2511NoNo
17241494COMPOSITIONS AND METHODS FOR TREATING SECONDARY TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIUM INFECTIONSApril 2021July 2024Abandon3921YesNo
17275892ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONSMarch 2021October 2023Allow3121YesNo
17191490Recombinant Acinetobacter baumannii strain AB5075March 2021June 2024Abandon4031NoNo
17175702MULTI-FUNCTIONAL BIOFERTILIZERFebruary 2021December 2024Abandon4611NoNo
17266780COMPOSITION FOR BIOLOGICAL CONTROL OF PHYTONEMATODESFebruary 2021January 2025Abandon4720NoNo
17265610MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDESFebruary 2021March 2023Allow2521YesNo
17264749METHOD FOR IMMUNOLOGICALLY DETECTING MYCOPLASMA PNEUMONIAEJanuary 2021October 2022Abandon2111NoNo
17157787Method of Treating Cervical VertigoJanuary 2021December 2023Abandon3420NoNo
17151746ISOLATED POLYNUCLEOTIDE INCLUDING PROMOTER REGION, HOST CELL INCLUDING THE SAME AND METHOD OF EXPRESSING A TARGET GENE USING THE HOST CELLJanuary 2021June 2023Allow2921NoNo
17141515CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021March 2024Allow3831NoNo
17141501CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021January 2024Abandon3621NoNo
17141477CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021January 2024Allow3611NoNo
17141533CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021March 2024Allow3831NoNo
17141566CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021September 2023Allow3312NoNo
17141554CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USEJanuary 2021March 2024Allow3831NoNo
17111115INSECTICIDAL POLYPEPTIDES HAVING IMPROVED ACTIVITY SPECTRUM AND USES THEREOFDecember 2020January 2023Allow2531YesNo
17103275SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOFNovember 2020June 2023Allow3011NoNo
17095427COMPOSITIONS COMPRISING BACTERIAL STRAINSNovember 2020July 2023Abandon3221NoNo
16949235Pet Food Compositions Including Probiotics and Methods of Manufacture and Use ThereofOctober 2020July 2022Allow2110NoNo
17076616BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITESOctober 2020October 2024Allow4841YesNo
16974113Method and apparatus to search for, find, collect and confirm the presence of ptentially dangerous airborne particles such as COVID-19 VIRUSOctober 2020January 2023Abandon2801NoNo
17029672BACILLUS COMPOSITIONS AND METHODS OF USE WITH RUMINANTSSeptember 2020July 2022Allow2220NoNo
17024746Genetically Modified Nitrogen Fixing Bacteria and Uses ThereofSeptember 2020April 2025Allow5520NoNo
17025706Enterococcus gallinarum flagellin polypeptidesSeptember 2020July 2023Allow3421NoNo
16979045USES OF CYANOBACTERIUM EXTRACELLULAR POLYMER, COMPOSITIONS, COATED SURFACES OR ARTICLESSeptember 2020February 2024Abandon4101NoNo
16978870Antibodies to USPA2September 2020June 2024Allow4541NoNo
16977692NANOVESICLES DERIVED FROM COPROCOCCUS SP. BACTERIA, AND USE THEREOFSeptember 2020August 2024Abandon4811NoNo
17005961IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINESAugust 2020January 2023Abandon2821YesNo
16997781CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGOAugust 2020June 2023Abandon3421NoNo
16997484COMPOSITIONAugust 2020June 2024Abandon4631YesNo
16968507COMBINATION OF A TETANUS TOXOID, ANTI-OX40 ANTIBODY AND/OR ANTI-PD-1 ANTIBODY TO TREAT TUMORSAugust 2020March 2023Abandon3121NoNo
16985589VACCINE COMPOSITION AGAINST STREPTOCOCCUS SUIS INFECTIONAugust 2020March 2024Allow4341YesNo
16966853FECAL FUNGOME AND THERAPEUTIC EFFICACY OF FECAL MICROBIOTA TRANSPLANTATIONJuly 2020March 2023Abandon3121YesNo
16943763ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USEJuly 2020August 2021Allow1311NoNo
16935899COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASESJuly 2020January 2023Abandon2921NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZEMAN, ROBERT A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
11
(57.9%)
Examiner Reversed
8
(42.1%)
Reversal Percentile
63.8%
Higher than average

What This Means

With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
122
Allowed After Appeal Filing
27
(22.1%)
Not Allowed After Appeal Filing
95
(77.9%)
Filing Benefit Percentile
26.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ZEMAN, ROBERT A - Prosecution Strategy Guide

Executive Summary

Examiner ZEMAN, ROBERT A works in Art Unit 1645 and has examined 912 patent applications in our dataset. With an allowance rate of 50.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner ZEMAN, ROBERT A's allowance rate of 50.7% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ZEMAN, ROBERT A receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ZEMAN, ROBERT A is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +30.8% benefit to allowance rate for applications examined by ZEMAN, ROBERT A. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 41.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 74.0% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 70.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.9% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.2% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.